Fulgent Genetics price target raised to $25 from $24 at Raymond James

Raymond James analyst Andrew Cooper raised the firm’s price target on Fulgent Genetics (FLGT) to $25 from $24 and keeps an Outperform rating on the shares. Fulgent’s Q1 print featured revenues slightly ahead of estimates and profitability stronger on better operating expenses, with EPS aided by lower share count from repurchases, and the reiterated guidance screens conservative, the analyst tells investors in a research note. The firm says there were “few major surprises” from Q1, and trends heading into the remainder of the year are on track and could deliver upside.